News & Regulatory Updates
Peptide regulation changes faster than most reference sites keep up with. This is where we track what actually changed, what it means in practice, and — just as often — what did not change despite the headlines.
Every article cites primary sources and carries the date its legal position was last reviewed. None of it is legal advice — see our disclaimer.
Latest
“Research Use Only” Is Not a Legal Shield — and Prosecutors Have Used It as Evidence
The disclaimer does not merely fail. In case after case it supplied the government’s fraud element, converting a 1-year misdemeanour into a 3-year felony.
More coverage
What Actually Happens When a Peptide Order Is Stopped at the Border
There is no personal-use exemption for peptides. Because most orders fall under $2,500, the realistic outcome is administrative destruction with no export option and no refund.
No Peptide Is a Federally Scheduled Controlled Substance — and the SARMs Control Act Never Passed
Two bills, two deaths in committee, zero enacted law — yet the “SARMs Control Act” is widely described as binding. Here is what the statute books actually say.
FDA Schedules PCAC Review of 12 Peptides for Compounding Access Under Section 503A
A Federal Register notice scheduled advisory-committee review of 12 peptides previously barred from compounding. It starts a process — it does not make anything legal.